Eric Hoyeon Song, MD, PhD
Associate Research ScientistDownloadHi-Res Photo
Cards
Appointments
Ophthalmology
Primary
Education
MD
Yale University (2022)
Yale University (2022)
PhD
Yale University, Immunobiology (2020)
Yale University, Immunobiology (2020)
Contact Info
Appointments
Ophthalmology
Primary
Education
MD
Yale University (2022)
Yale University (2022)
PhD
Yale University, Immunobiology (2020)
Yale University, Immunobiology (2020)
Contact Info
Appointments
Ophthalmology
Primary
Education
MD
Yale University (2022)
Yale University (2022)
PhD
Yale University, Immunobiology (2020)
Yale University, Immunobiology (2020)
Contact Info
About
Titles
Associate Research Scientist
Biography
Eric Song received his undergraduate training at University of Southern California in biochemistry. After graduating, he joined Justin Hanes' lab as a master's student studying how to better design nanoparticles to deliver genes and drugs into the brain. After a post-bacc in Mark Saltzman's lab at Yale expanding his skillset as a biomedical engineer, he entered the Yale Medical Scientist Training Program for his MD and PhD degrees. For his PhD he worked with Akiko Iwasaki to answer questions regarding why immune responses in the brain are different than the rest of the body. Eric continues to perform research in trying to understand and manipulate immune responses in immune privileged tissues to help design new therapies for diseases without cures.
Appointments
Ophthalmology
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- MD
- Yale University (2022)
- PhD
- Yale University, Immunobiology (2020)
- MS
- Johns Hopkins University (2015)
- BS
- University of Southern California (2014)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Eric Hoyeon Song's published research.
Akiko Iwasaki, PhD
Marcus Bosenberg, MD, PhD
Carmen Jane Booth, DVM, PhD
Goran Micevic, MD, PhD
Harriet Kluger, MD
Kim Blenman, PhD, MS
Publications
2023
Developing synthetic tools to decipher the tumor–immune interactome
Weizman O, Luyten S, Lu P, Song E, Qin K, Mostaghimi D, Ring A, Iwasaki A. Developing synthetic tools to decipher the tumor–immune interactome. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2306632120. PMID: 37871202, PMCID: PMC10622925, DOI: 10.1073/pnas.2306632120.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune cellsImmune-based therapiesTumor-immune cell interactionsDifferent immunotherapiesRetroviral reportersSensitive tumorsImmune surveillanceTumor subtypesTumor microenvironmentSynthetic Notch receptorCell interactionsCell contactTissue functionTissue locationNotch receptorsVivoOptimal tissue functionCellsComprehensive landscapeImmunotherapyTherapyTumorsImmunogenicitySubtypesType 2 Dendritic Cells Orchestrate a Local Immune Circuit to Confer Antimetastatic Immunity
Weizman O, Luyten S, Krykbaeva I, Song E, Mao T, Bosenberg M, Iwasaki A. Type 2 Dendritic Cells Orchestrate a Local Immune Circuit to Confer Antimetastatic Immunity. The Journal Of Immunology 2023, 210: 1146-1155. PMID: 36881866, PMCID: PMC10067787, DOI: 10.4049/jimmunol.2200697.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsType 2 dendritic cellsMetastatic burdenImmune circuitsDendritic cellsConventional type 2 dendritic cellsSyngeneic murine melanomaNK cell compartmentImmune cell responsesColon cancer modelEarly metastatic seedingMetastatic controlTranscription factor IRF3DC populationsNK cellsProinflammatory cytokinesNucleic acid sensingPrimary tumorEffector responsesMetastatic spreadDisease outcomeIntracardiac injectionT cellsInitial immunityTissue-specific ablationCancer modelResponse to: Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect
Takahashi T, Stoiljkovic M, Song E, Gao X, Yasumoto Y, Kudo E, Carvalho F, Kong Y, Park A, Shanabrough M, Szigeti-Buck K, Liu Z, Kristant A, Zhang Y, Sulkowski P, Glazer P, Kaczmarek L, Horvath T, Iwasaki A. Response to: Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect. Neuron 2023, 111: 612-613. PMID: 36863323, DOI: 10.1016/j.neuron.2023.02.006.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords
2021
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature 2021, 598: 682-687. PMID: 34671158, PMCID: PMC8555464, DOI: 10.1038/s41586-021-03994-2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsCell Line, TumorDNA-Binding ProteinsEpigenesis, GeneticGene SilencingHeterochromatinHistone-Lysine N-MethyltransferaseHumansInterferon Type IJumonji Domain-Containing Histone DemethylasesMaleMelanomaMiceMice, Inbred C57BLMice, KnockoutNuclear ProteinsRepressor ProteinsRetroelementsTumor EscapeConceptsImmune checkpoint blockadeImmune evasionCheckpoint blockadeImmune responseAnti-tumor immune responseRobust adaptive immune responseTumor immune evasionAnti-tumor immunityAdaptive immune responsesType I interferon responseDNA-sensing pathwayMouse melanoma modelImmunotherapy resistanceMost patientsCurrent immunotherapiesTumor immunogenicityImmune memoryMelanoma modelCytosolic RNA sensingRole of KDM5BConsiderable efficacyInterferon responseImmunotherapyEpigenetic therapyBlockade
News
News
- February 28, 2024Source: YaleNews
In Fight Against Brain Pathogens, the Eyes Have It
- November 02, 2022Source: Inside Precision Medicine
Mismatch Repair Genes May Be Key to Immunotherapy Response
- November 01, 2022Source: YaleNews
Why Immunotherapy Works Well for Some Cancer Patients, but Not Others
- October 27, 2022
New Findings on Endometrial Cancer Treated With Pembrolizumab
Get In Touch
Contacts
Email